Shanafelt, T. D., Wang, X. V., Hanson, C. A., Paietta, E., O’Brien, S., Barrientos, J., … Kay, N. E. (2025). Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Adv, 9(1), 224–228. https://doi.org/10.1182/bloodadvances.2024013474

Shanafelt, Tait D., Xin Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, et al. “Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.” Blood Adv 9, no. 1 (January 14, 2025): 224–28. https://doi.org/10.1182/bloodadvances.2024013474.

Shanafelt TD, Wang XV, Hanson CA, Paietta E, O’Brien S, Barrientos J, et al. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Adv. 2025 Jan 14;9(1):224–8.

Shanafelt, Tait D., et al. “Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.” Blood Adv, vol. 9, no. 1, Jan. 2025, pp. 224–28. Pubmed, doi:10.1182/bloodadvances.2024013474.

Shanafelt TD, Wang XV, Hanson CA, Paietta E, O’Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Adv. 2025 Jan 14;9(1):224–228.